These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7793303)

  • 1. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause.
    Campagnoli C; Biglia N; Peris C; Sismondi P
    Gynecol Endocrinol; 1995 Mar; 9(1):67-74. PubMed ID: 7793303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables.
    Campagnoli C; Biglia N; Belforte P; Botta D; Pedrini E; Sismondi P
    Eur J Gynaecol Oncol; 1992; 13(2):139-54. PubMed ID: 1587291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
    Weissberger AJ; Ho KK; Lazarus L
    J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of progestins on the circulating IGF-I system.
    Campagnoli C; Abbà C; Ambroggio S; Peris C
    Maturitas; 2003 Dec; 46 Suppl 1():S39-44. PubMed ID: 14670644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report.
    Campagnoli C; Biglia N; Lanza MG; Lesca L; Peris C; Sismondi P
    Maturitas; 1994 May; 19(1):25-31. PubMed ID: 7935029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages.
    Bellantoni MF; Harman SM; Cho DE; Blackman MR
    J Clin Endocrinol Metab; 1991 Jan; 72(1):172-8. PubMed ID: 1824707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HRT and breast cancer risk: a clue for interpreting the available data.
    Campagnoli C; Biglia N; Cantamessa C; Lesca L; Sismondi P
    Maturitas; 1999 Dec; 33(3):185-90. PubMed ID: 10656496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The influence of estrogen and progestogen replacement on growth hormone activity in women with hypopituitarism].
    Isotton AL; Wender MC; Czepielewski MA
    Arq Bras Endocrinol Metabol; 2008 Jul; 52(5):901-16. PubMed ID: 18797598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels.
    Campagnoli C; Biglia N; Altare F; Lanza MG; Lesca L; Cantamessa C; Peris C; Fiorucci GC; Sismondi P
    Gynecol Endocrinol; 1993 Dec; 7(4):251-8. PubMed ID: 8147234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjugated estrogens and breast cancer risk.
    Campagnoli C; Ambroggio S; Biglia N; Sismondi P
    Gynecol Endocrinol; 1999 Dec; 13 Suppl 6():13-9. PubMed ID: 10862264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients.
    Ng EH; Ji CY; Tan PH; Lin V; Soo KC; Lee KO
    Ann Surg Oncol; 1998 Mar; 5(2):194-201. PubMed ID: 9527274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis.
    Heald A; Selby PL; White A; Gibson JM
    Am J Obstet Gynecol; 2000 Sep; 183(3):593-600. PubMed ID: 10992179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between critical period of estrogen exposure and circulating levels of insulin-like growth factor-I (IGF-I) in breast cancer: evidence from a case-control study.
    Wu MH; Chou YC; Chou WY; Hsu GC; Chu CH; Yu CP; Yu JC; Sun CA
    Int J Cancer; 2010 Jan; 126(2):508-14. PubMed ID: 19585556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer.
    Corsello SM; Rota CA; Putignano P; Della Casa S; Barnabei A; Migneco MG; Vangeli V; Barini A; Mandalà M; Barone C; Barbarino A
    Eur J Endocrinol; 1998 Sep; 139(3):309-13. PubMed ID: 9758441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.
    Campagnoli C; Clavel-Chapelon F; Kaaks R; Peris C; Berrino F
    J Steroid Biochem Mol Biol; 2005 Jul; 96(2):95-108. PubMed ID: 15908197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.